c. Parasympathomimetics, Parasympatholytics, Sympathomimetics, sympatholytics. d. Neuromuscular blocking agents and skeletal muscle relaxants (peripheral). e. Local anesthetic agents. f. Drugs used in myasthenia gravis and glaucoma

Reading File

Finding Sources

Now let me read the most relevant sections from Katzung and Lippincott (standard pharmacology textbooks) for all topics simultaneously:

Reading File

Now let me read more detailed sections - cholinergic drugs from Katzung and myasthenia/glaucoma drugs:

Finding Sources

Reading File

I now have sufficient information to write comprehensive 8-mark answers for all topics. Let me now synthesize everything:Here are detailed 8-mark answers for each topic (c through f):

c. Parasympathomimetics, Parasympatholytics, Sympathomimetics, and Sympatholytics

PARASYMPATHOMIMETICS (Cholinomimetics)

Definition: Drugs that mimic the actions of the parasympathetic nervous system by stimulating muscarinic and/or nicotinic receptors, or by inhibiting acetylcholinesterase (AChE).

Classification

1. Direct-Acting (Receptor Agonists)

These drugs bind directly to cholinoceptors (muscarinic or nicotinic):

Drug	Type	Key Properties
Acetylcholine (ACh)	Muscarinic + Nicotinic	Rapidly hydrolyzed; short action; rarely used systemically
Bethanechol	Muscarinic (M3)	Not hydrolyzed by AChE; used for urinary retention, paralytic ileus
Carbachol	Muscarinic + Nicotinic	Resistant to AChE; used in glaucoma (eye drops)
Pilocarpine	Muscarinic (M3)	Tertiary amine; penetrates CNS; drug of choice in glaucoma emergencies
Methacholine	Muscarinic	Used in bronchial challenge test for asthma

2. Indirect-Acting (Anticholinesterase Agents)

These inhibit AChE, thus allowing ACh to accumulate:

Reversible inhibitors:

Physostigmine - tertiary amine, crosses BBB; used for glaucoma and atropine/tricyclic antidepressant overdose
Neostigmine - quaternary amine, does NOT cross BBB; used in myasthenia gravis and to reverse NM blockade
Pyridostigmine - longer acting than neostigmine; preferred oral drug in myasthenia gravis
Edrophonium - very short-acting (2-5 min); used in the Tensilon test to diagnose myasthenia gravis
Rivastigmine, Donepezil, Galantamine - used in Alzheimer's disease

Irreversible inhibitors (organophosphates):

Sarin, tabun (nerve agents), malathion, parathion (insecticides)
Bind covalently to AChE, causing cholinergic crisis (SLUDGE: Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis; plus miosis, bronchospasm, bradycardia)
Treatment: Atropine (for muscarinic effects) + Pralidoxime/2-PAM (to regenerate AChE before "aging")

Pharmacological Effects

Eye: Miosis, spasm of accommodation (ciliary muscle contraction)
Heart: Bradycardia, decreased conduction velocity (SA/AV node)
Lungs: Bronchoconstriction, increased secretions
GIT: Increased motility and secretions, relaxed sphincters
Bladder: Contraction of detrusor, relaxation of trigone/sphincter (promotes micturition)
Glands: Increased salivation, lacrimation, sweating

PARASYMPATHOLYTICS (Anticholinergics / Muscarinic Antagonists)

Definition: Drugs that competitively block muscarinic receptors, opposing parasympathetic effects. They do not block nicotinic receptors at standard doses.

Classification

Naturally occurring alkaloids:

Atropine - prototype; reversibly blocks all subtypes of muscarinic receptors; crosses BBB
Scopolamine (Hyoscine) - more CNS effects; used for motion sickness and pre-anesthesia
Hyoscyamine - more potent than atropine; used in GI spasm

Synthetic/semisynthetic:

Ipratropium - inhaled; bronchodilator; used in COPD and asthma; quaternary, does not cross BBB
Tiotropium - long-acting inhaled; once daily for COPD
Benztropine, Trihexyphenidyl - used in Parkinson's disease (reduce tremor)
Oxybutynin, Tolterodine, Solifenacin - M3 antagonists; used for overactive bladder
Glycopyrrolate - quaternary; used perioperatively to reduce secretions; does not cross BBB

Pharmacological Effects (Dose-Dependent - "ABCDE" mnemonic)

Antisecretory: decreased saliva, tears, sweat, bronchial secretions
Bronchodilation
Cardiac acceleration (tachycardia - blocks M2 at SA node)
Dilation of pupils (mydriasis) + cycloplegia
Emptying of bladder impaired (urinary retention)

Atropine Dose-Response:

0.5 mg: slight bradycardia (paradoxical - blocks presynaptic M1 autoinhibition)
1 mg: tachycardia, dry mouth
2 mg: tachycardia, palpitations, dry skin, mydriasis
5 mg: hot dry skin, difficulty swallowing, restlessness
10 mg: hallucinations, coma, respiratory depression

Uses of Atropine:

Pre-anesthetic medication (reduce secretions)
Bradycardia/AV block
Organophosphate poisoning antidote
Ophthalmology (mydriasis/cycloplegia)
Peptic ulcer (now largely replaced)

Contraindications: Narrow-angle glaucoma, prostatic hypertrophy, paralytic ileus, tachycardia

SYMPATHOMIMETICS (Adrenomimetics)

Definition: Drugs that mimic sympathetic nervous system effects by acting on adrenergic receptors (α and β) or by enhancing norepinephrine/epinephrine release.

Classification

1. Direct-Acting (Catecholamines)

Drug	Receptor	Main Uses
Epinephrine (Adrenaline)	α1, α2, β1, β2	Anaphylaxis, cardiac arrest, glaucoma (reduces aqueous humor), with LA
Norepinephrine (Noradrenaline)	α1, α2, β1	Septic shock (vasopressor)
Dopamine	D1, D2, β1, α1 (dose-dependent)	Cardiogenic shock; low dose - renal vasodilation
Dobutamine	β1 > β2, α1	Heart failure - positive inotrope
Isoproterenol (Isoprenaline)	β1, β2	Bronchospasm, AV block (now largely replaced)
Salbutamol (Albuterol)	β2 selective	Bronchial asthma (reliever)
Salmeterol/Formoterol	β2 (long-acting)	Asthma/COPD (controller)
Phenylephrine	α1 selective	Nasal decongestant, mydriasis, hypotension

2. Indirect-Acting

Amphetamine - releases NE and DA from presynaptic terminals; CNS stimulant
Tyramine - releases NE (danger in patients on MAO inhibitors - "cheese reaction")
Cocaine - blocks NE/DA/5-HT reuptake; also a local anesthetic

3. Mixed-Acting

Ephedrine - both direct (α, β) and indirect effects; nasal decongestant; used in spinal anesthesia-induced hypotension

Receptor-Based Effects

α1 stimulation: Vasoconstriction, mydriasis, contraction of bladder trigone/sphincter
α2 stimulation: Presynaptic - inhibits NE release (negative feedback); in CNS - decreases sympathetic outflow (sympatholytic effect of clonidine)
β1 stimulation: +ve chronotropy, +ve inotropy, increased conduction velocity, increased renin release
β2 stimulation: Bronchodilation, vasodilation (skeletal muscle), uterine relaxation (tocolysis), glycogenolysis

SYMPATHOLYTICS (Adrenolytics)

Definition: Drugs that reduce adrenergic activity, either by blocking adrenergic receptors or by reducing release of norepinephrine.

Classification

1. Alpha Blockers

Drug	Type	Uses
Phentolamine	Non-selective (α1+α2), reversible	Pheochromocytoma diagnosis/crisis, cocaine toxicity
Phenoxybenzamine	Non-selective, irreversible	Pheochromocytoma pre-op
Prazosin, Doxazosin, Terazosin	Selective α1, reversible	Hypertension, BPH
Tamsulosin	α1A selective	BPH (minimal BP effect)
Yohimbine	α2 antagonist	Research tool; erectile dysfunction

2. Beta Blockers

Drug	Selectivity	Special Properties	Uses
Propranolol	Non-selective (β1+β2)	Lipophilic, crosses BBB	Hypertension, angina, arrhythmia, migraine prophylaxis, hyperthyroidism
Metoprolol, Atenolol	β1 selective ("cardioselective")	Safer in asthmatics	Hypertension, heart failure, post-MI
Nadolol	Non-selective	Long duration	Hypertension
Labetalol, Carvedilol	α + β block	Vasodilatory	Hypertension, heart failure
Pindolol	Non-selective	Partial agonist (ISA)	Hypertension (less bradycardia)
Timolol	Non-selective (topical)	Reduces aqueous humor	Glaucoma
Esmolol	β1 selective, ultra-short	Given IV	Intraoperative hypertension/tachycardia

3. Centrally Acting Sympatholytics (α2 Agonists)

Clonidine - stimulates central α2 receptors → reduces sympathetic outflow → lowers BP; also used in opioid withdrawal, ADHD; rebound hypertension on abrupt withdrawal
Methyldopa - converted to α-methylnorepinephrine (false transmitter); first-line in pregnancy-induced hypertension
Guanfacine, Guanabenz - similar to clonidine

4. Adrenergic Neuron Blockers

Reserpine - depletes NE/5-HT/DA from storage vesicles; used for hypertension; side effects: depression, Parkinsonism
Guanethidine - blocks NE release; used in severe hypertension (now rarely)

d. Neuromuscular Blocking Agents and Skeletal Muscle Relaxants (Peripheral)

Neuromuscular Junction (NMJ) - Review

At the motor end plate, ACh is released and binds to nicotinic receptors (NM type) composed of 5 subunits (2α, β, γ/ε, δ). Binding of 2 ACh molecules opens the ion channel, causing end plate depolarization and muscle contraction. ACh is then rapidly degraded by AChE.

Classification of NMJ Blocking Agents

I. NON-DEPOLARIZING (Competitive) Blockers

Mechanism: Compete with ACh for nicotinic receptor binding sites at the NMJ without activating them. They do NOT open the ion channel.

Prototype: d-Tubocurarine (Curare)

Characteristics of Non-Depolarizing Blockade:

No initial muscle fasciculations
Train-of-four (TOF): "Fade" (progressive decrease in contraction strength)
Posttetanic potentiation: Present
Reversed by: Neostigmine, edrophonium (anticholinesterases)
Augmented by: Volatile anesthetics, aminoglycosides, hypocalcemia, hypermagnesemia, hypothermia

Drugs and Properties:

Drug	Class	Duration	Elimination	Notes
d-Tubocurarine	Benzylisoquinoline	Long	Renal	Histamine release, ganglionic block
Atracurium	Benzylisoquinoline	Intermediate	Hofmann elimination	Metabolized spontaneously in plasma; safe in renal/hepatic failure; releases histamine
Cisatracurium	Benzylisoquinoline	Intermediate	Hofmann elimination	Less histamine release than atracurium
Mivacurium	Benzylisoquinoline	Short	Plasma cholinesterase	Avoid in pseudocholinesterase deficiency
Pancuronium	Steroidal	Long	Renal	Tachycardia (blocks M2); used in ICU
Vecuronium	Steroidal	Intermediate	Biliary/Hepatic	No cardiovascular effects; safe in cardiac patients
Rocuronium	Steroidal	Intermediate	Biliary	Fastest onset of non-depolarizers; can substitute for succinylcholine in RSI; reversed by sugammadex
Pipecuronium	Steroidal	Long	Renal	No cardiovascular effects

Key Points - Pharmacokinetics:

All are highly polar; inactive orally; must be given parenterally (IV)
Volume of distribution slightly larger than blood volume (80-140 mL/kg)
Drugs eliminated by kidney have longer half-lives (longer duration >35 min)
Drugs eliminated by liver have shorter half-lives (shorter duration)
Steroidal relaxants are metabolized to 3-hydroxy metabolites (40-80% as potent) - can cause prolonged paralysis in ICU if parent drug accumulates

Reversal of Non-Depolarizing Blockade:

Neostigmine (+ glycopyrrolate or atropine to prevent bradycardia)
Sugammadex - encapsulates (chelates) rocuronium and vecuronium specifically; can reverse even deep blockade rapidly

II. DEPOLARIZING BLOCKERS

Prototype: Succinylcholine (Suxamethonium)

Mechanism: Structurally resembles ACh (two linked ACh molecules). Binds to nicotinic receptor and produces persistent depolarization. Unlike ACh, it is NOT hydrolyzed by AChE - only by plasma pseudocholinesterase (butyrylcholinesterase), which is slower.

Two phases of blockade:

Feature	Phase I (Depolarizing)	Phase II (Desensitization)
Mechanism	Persistent end-plate depolarization	Receptor desensitization
Onset	Preceded by fasciculations	After prolonged/repeated dosing
TOF	Constant diminished response (no fade); TOF ratio = 1.0	Fade (like non-depolarizing)
Tetanic stimulation	Sustained (no fade)	Fade
Effect of neostigmine	Augments (worsens)	Reverses (antagonizes)
Effect of non-depolarizing drugs	Antagonistic	Augmented

Pharmacokinetics:

Duration: 4-8 minutes (very short) - shortest acting NM blocker
Metabolized by plasma pseudocholinesterase
Pseudocholinesterase deficiency (genetic variant): prolonged blockade (apnea for hours); treatment: fresh frozen plasma (FFP) or fresh blood

Advantages:

Fastest onset of all NM blockers (45-60 seconds)
Shortest duration (4-8 min)
Drug of choice for rapid sequence intubation (RSI) and emergency airway

Disadvantages/Adverse Effects:

Fasciculations (initial muscle twitching) - can cause post-op myalgia
Hyperkalemia - potassium released during depolarization; dangerous in burns, spinal cord injury, crush injuries, denervation injuries (use with extreme caution)
Increased intragastric pressure (due to fasciculations)
Increased intraocular pressure - contraindicated in penetrating eye injury
Increased intracranial pressure
Bradycardia (especially after repeated doses)
Malignant hyperthermia (MH) - rare but life-threatening hypermetabolic crisis; triggers: succinylcholine + volatile anesthetics (halothane, isoflurane, etc.); treatment: dantrolene (blocks Ca²+ release from sarcoplasmic reticulum)
Phase II blockade with repeated dosing
Contraindicated in: genetic pseudocholinesterase deficiency, hyperkalemia risk, penetrating eye injury, malignant hyperthermia susceptibility

Centrally Acting Skeletal Muscle Relaxants (Brief Note)

These act in the CNS rather than the NMJ:

Baclofen - GABA-B agonist; used for spasticity (multiple sclerosis, spinal cord injury)
Diazepam - GABA-A positive modulator; anti-spastic, anti-anxiety
Cyclobenzaprine - related to tricyclics; used for acute muscle spasm
Tizanidine - central α2 agonist; reduces spasticity; also has antihypertensive properties

Dantrolene (unique - peripheral + central):

Acts directly on skeletal muscle by blocking Ca²+ release from sarcoplasmic reticulum
Used for malignant hyperthermia (drug of choice) and neuroleptic malignant syndrome
Also used for chronic spasticity (cerebral palsy, MS)

e. Local Anesthetic Agents

Definition

Local anesthetics (LAs) are drugs that reversibly block nerve conduction when applied locally to a nerve, thereby preventing sensation (and movement) in a localized area without loss of consciousness.

Chemistry and Structure

A typical LA molecule (e.g., lidocaine, procaine) has three parts:

Lipophilic aromatic ring (benzene ring)
Intermediate chain - either an ESTER or AMIDE linkage (determines classification)
Hydrophilic tertiary amine (pKa 7.5-9.0) - partially protonated at physiological pH

Classification:

Feature	ESTERS	AMIDES
Linkage	-CO-O-	-NH-CO-
Examples	Procaine, Chloroprocaine, Cocaine, Tetracaine, Benzocaine	Lidocaine, Bupivacaine, Ropivacaine, Mepivacaine, Prilocaine, Etidocaine
Metabolism	Plasma pseudocholinesterase	Hepatic microsomes
Metabolite	PABA (para-aminobenzoic acid)	No PABA
Allergy	PABA may cause allergic reactions	True allergy rare
Stability	Less stable	More stable
Duration	Shorter (mostly)	Longer

Memory aid: Esters have one "i" in their name; Amides have two "i"s - lIdocaIne, bupIvacaIne

Mechanism of Action

The uncharged (free base) form of the LA crosses the neuronal cell membrane (lipid bilayer) to enter the axoplasm
Inside the cell, the molecule is re-protonated to the charged (cationic) form
The cationic form enters and binds to the intracellular side of voltage-gated Na⁺ channels in the inactivated state
This physically blocks Na⁺ channel, preventing Na⁺ influx
The action potential cannot be generated or propagated → nerve conduction is blocked
This is called use-dependent (frequency-dependent) block - faster-firing nerves are blocked more effectively

Order of blockade (smallest to largest fiber):

Small, unmyelinated C fibers (pain, temperature) → blocked first
Small, myelinated B fibers (preganglionic autonomic)
Large, myelinated A-delta fibers (sharp pain, touch)
A-beta fibers (touch, pressure, proprioception)
A-alpha fibers (motor, proprioception) → blocked last

Therefore, pain is blocked before touch, and touch before motor function ("differential block"). This is useful in labor epidurals (pain relief without total motor paralysis).

Factors Affecting Activity

pKa:

Higher pKa = more ionized at tissue pH = slower onset (less free base to cross membrane)
Chloroprocaine (pKa 9.1) - slower onset; lidocaine (pKa 7.9) - faster onset

Lipid Solubility:

More lipophilic = greater potency + longer duration (e.g., bupivacaine, etidocaine)

Protein Binding:

More protein-bound = longer duration (bupivacaine 95% bound - long duration)

Vascularity of injection site:

High vascularity → rapid absorption → shorter duration; hence epinephrine is added to cause local vasoconstriction

Tissue pH:

Infected/acidic tissue (pus): more ionized form, less free base → reduced efficacy of LA (explains why LAs "don't work" in infected tissue)

Addition of Epinephrine (Vasoconstrictor)

Causes local vasoconstriction → slows absorption of LA into systemic circulation
Prolongs duration of action (30-50%)
Reduces systemic toxicity
Reduces bleeding
Contraindicated in: ring blocks (digits, penis, ears, nose) - risk of ischemia/gangrene; cardiac arrhythmias; severe hypertension

Individual Drugs

Drug	Class	Onset	Duration	Uses	Special Notes
Lidocaine	Amide	Fast	Intermediate (1-2 hr)	Infiltration, epidural, IV regional (Bier block), topical, ventricular arrhythmia	Most widely used; also class IB antiarrhythmic
Bupivacaine	Amide	Slow	Long (4-8 hr)	Epidural (obstetrics), spinal, peripheral nerve blocks	More cardiotoxic than others; L-isomer (levobupivacaine) safer
Ropivacaine	Amide	Intermediate	Long	Epidural, peripheral nerve blocks	Less motor block than bupivacaine; less cardiotoxic
Procaine	Ester	Slow	Short	Infiltration	Prototype ester; low toxicity
Cocaine	Ester	Fast	Medium	ENT topical only	Only LA with vasoconstrictive properties; sympathomimetic
Tetracaine	Ester	Slow	Long	Spinal anesthesia, topical ophthalmology	High potency
Chloroprocaine	Ester	Very fast	Very short	Epidural	Fastest onset; safest for IV use in obstetrics
Prilocaine	Amide	Fast	Intermediate	EMLA cream (with lidocaine), IV regional	Can cause methemoglobinemia
Benzocaine	Ester	Fast	Short	Topical only (surface anesthesia)	Insoluble; for mucous membranes

EMLA Cream: Eutectic Mixture of Local Anesthetics (lidocaine 2.5% + prilocaine 2.5%); used for topical anesthesia before venipuncture, especially in children.

Systemic Toxicity

CNS Toxicity (occurs at lower plasma concentrations):

Early: Tinnitus, circumoral numbness, metallic taste, lightheadedness, visual disturbances
Intermediate: Muscle twitching, tremors, seizures (excitation then depression of CNS)
Late: Respiratory depression, coma

Cardiovascular Toxicity (requires higher plasma concentrations):

Bradycardia, hypotension, heart block
Bupivacaine can cause refractory ventricular fibrillation - very cardiotoxic
Treatment: 20% Intralipid (lipid emulsion therapy) - acts as a "lipid sink" to extract bupivacaine from cardiac tissue

Order of toxicity (most to least): Tetracaine > Bupivacaine > Lidocaine > Prilocaine > Procaine

Allergic Reactions:

True allergy is rare with amides
Esters produce PABA → can cause true IgE-mediated reactions
Often "allergy" is actually due to preservatives (methylparaben) in the formulation

f. Drugs Used in Myasthenia Gravis and Glaucoma

DRUGS USED IN MYASTHENIA GRAVIS (MG)

Pathophysiology

Myasthenia gravis is an autoimmune disease caused by antibodies against nicotinic acetylcholine receptors (AChR) at the NMJ. This reduces the number of functional receptors, impairing neuromuscular transmission. Result: fatigable muscle weakness that worsens with repeated activity.

Key features:

Ptosis and diplopia (ocular muscles affected first/most often)
Bulbar weakness (dysphagia, dysarthria)
Respiratory muscle weakness (myasthenic crisis)
Positive Tensilon (edrophonium) test
Anti-AChR antibodies in ~85% of patients (anti-MuSK in ~10%)

Diagnosis - The Tensilon (Edrophonium) Test

IV edrophonium (2 mg test dose, then 8 mg) rapidly inhibits AChE
Temporary improvement in muscle strength within 60 seconds = positive test
Confirms MG (distinguishes from cholinergic crisis, where strength worsens)

Treatment Drugs

1. Anticholinesterase Agents (Symptomatic Treatment - First Line)

These increase ACh at NMJ, enhancing transmission despite reduced receptor numbers:

Drug	Route	Duration	Notes
Pyridostigmine (Mestinon)	Oral (also IV)	4-6 hours	Drug of choice for long-term MG management; quaternary amine; does not cross BBB
Neostigmine	Oral/IV/IM	2-4 hours	Shorter acting; used IV/IM in myasthenic crisis and post-operative MG
Edrophonium	IV only	5-10 minutes	Diagnosis only (Tensilon test)

Muscarinic side effects of anticholinesterases:

SLUDGE (Salivation, Lacrimation, Urination, Defecation, GI cramps, Emesis)
Managed with atropine or glycopyrrolate given alongside

Cholinergic Crisis vs Myasthenic Crisis:

Feature	Myasthenic Crisis	Cholinergic Crisis
Cause	Insufficient drug	Too much anticholinesterase
Muscle weakness	Yes	Yes
Edrophonium test	Improves	Worsens
Pupils	Normal/dilated	Miotic
Secretions	Normal	Excessive (SLUDGE)
Treatment	Increase dose of pyridostigmine	Stop anticholinesterase; atropine

2. Immunosuppressants (Disease-Modifying Therapy)

These reduce autoantibody production:

Drug	Mechanism	Onset	Notes
Corticosteroids (Prednisone)	Broad immunosuppression	2-4 weeks	Initial worsening may occur; start low and taper up; most commonly used
Azathioprine	Antimetabolite; reduces T/B cell proliferation	6-18 months	Steroid-sparing agent; most common maintenance immunosuppressant in MG
Mycophenolate mofetil	Inhibits purine synthesis	Months	Well-tolerated alternative to azathioprine
Cyclosporine/Tacrolimus	Calcineurin inhibitors	1-3 months	Used in refractory cases
Rituximab	Anti-CD20 (depletes B cells)	Months	Used in refractory MG, especially anti-MuSK positive

3. Thymectomy

The thymus harbors autoreactive T cells and produces AChR antibodies
Indicated for all patients with thymoma; recommended in generalized MG in patients <60 years
Clinical benefit may take years; ~35% achieve complete stable remission

4. Rapid Immunomodulation (for Crisis)

Plasmapheresis (Plasma Exchange): Removes circulating AChR antibodies; rapid onset (hours to days); used for myasthenic crisis or pre-operatively
IV Immunoglobulin (IVIG): Modulates immune response; onset in 3-5 days; safer than plasmapheresis; alternative for crisis

5. Newer Targeted Therapies

Eculizumab - anti-C5 complement inhibitor; approved for anti-AChR antibody-positive generalized MG refractory to conventional therapy
Efgartigimod - FcRn antagonist; reduces IgG (including AChR antibodies) levels

DRUGS USED IN GLAUCOMA

Pathophysiology

Glaucoma is characterized by increased intraocular pressure (IOP), which damages the optic nerve, causing visual field loss and blindness. IOP is determined by balance between aqueous humor production (by ciliary epithelium) and drainage (through trabecular meshwork → Canal of Schlemm → episcleral veins, and via uveoscleral route).

Types:

Open-angle glaucoma (chronic): Obstructed trabecular meshwork; treated pharmacologically long-term
Closed/Narrow-angle glaucoma (acute): Iris occludes drainage angle; emergency treatment; requires surgical iridectomy

Drugs That Reduce Aqueous Humor PRODUCTION

1. Beta-Adrenergic Blockers (Topical) - Most Widely Used

Drug	Selectivity	Notes
Timolol (0.25%, 0.5%)	Non-selective (β1+β2)	Most commonly used; once or twice daily; reduces aqueous secretion from ciliary epithelium
Betaxolol	β1-selective	Safer in asthma (less β2 blockade); but less effective than timolol
Carteolol, Levobunolol, Metipranolol	Non-selective	Alternative agents

Mechanism: Block β-receptors on ciliary epithelium → reduce cAMP → reduce aqueous humor production
Caution: May cause systemic effects (absorbed via nasolacrimal duct) - bradycardia, bronchospasm, exacerbate heart block, depression
Contraindications: Asthma, COPD, heart block, bradycardia, heart failure

2. Alpha-2 Agonists (Topical)

Brimonidine (0.2%) - highly selective α2; reduces aqueous production AND increases uveoscleral outflow; first-line alternative to beta-blockers; CNS side effects (sedation) possible
Apraclonidine - less selective; used short-term to prevent IOP spike after laser procedures
Epinephrine - older agent; α + β effects; reduces production and increases outflow

3. Carbonic Anhydrase Inhibitors (CAIs)

Mechanism: Carbonic anhydrase (CA) in ciliary body catalyzes formation of bicarbonate/H⁺, driving Na⁺ and water secretion. CAIs block this → reduce aqueous production by ~30-40%

Drug	Route	Notes
Dorzolamide	Topical (2%)	Minimal systemic absorption
Brinzolamide	Topical (1%)	Better tolerated locally than dorzolamide
Acetazolamide	Oral/IV	Systemic agent; used in acute angle-closure crisis; side effects: paresthesias, metabolic acidosis, kidney stones, hypokalemia; sulfonamide allergy caution
Methazolamide	Oral	Fewer systemic side effects than acetazolamide

Drugs That INCREASE Aqueous Humor Outflow

4. Prostaglandin F2α Analogs - CURRENT FIRST-LINE AGENTS for Open-Angle Glaucoma

Mechanism: Increase uveoscleral outflow (bypass trabecular meshwork via smooth muscle relaxation in ciliary body)
Drugs: Latanoprost, Bimatoprost, Travoprost, Tafluprost, Unoprostone
Dosing: Once daily (evening) - most convenient
Side effects: Increased iris pigmentation (brown color change - irreversible), hypertrichosis (increased lash growth - in Bimatoprost → used cosmetically as Lumigan), conjunctival hyperemia
Advantage: No systemic cardiovascular/pulmonary side effects; highly effective (20-30% IOP reduction)

5. Cholinomimetics (Miotics)

Mechanism: Stimulate M3 receptors on ciliary muscle → ciliary muscle contracts → opens trabecular meshwork → increased aqueous outflow through Schlemm's canal; also cause miosis (constriction of pupil - opens drainage angle in closed-angle glaucoma)
Drugs:
- Pilocarpine - drug of choice for emergency treatment of both open-angle and acute angle-closure glaucoma; effect in minutes; lasts 4-8 hours; tertiary amine; applied topically; also reverses atropine-induced mydriasis
- Carbachol - used when pilocarpine fails; also causes miosis
Side effects: Miosis (poor night vision), brow ache, blurred vision (ciliary spasm), myopia
Contraindications: Iritis, uveitis

6. Rho Kinase (ROCK) Inhibitors

Netarsudil - newest class; increases trabecular meshwork outflow; also reduces aqueous production; once daily
Ripasudil - available in Japan/Europe

Summary Table - Anti-Glaucoma Drugs by Mechanism

Class	Example Drugs	Mechanism	Route
Prostaglandin analogs	Latanoprost, bimatoprost	↑ uveoscleral outflow	Topical (1st line)
Beta blockers	Timolol, betaxolol	↓ aqueous production	Topical
Alpha-2 agonists	Brimonidine	↓ production + ↑ outflow	Topical
Carbonic anhydrase inhibitors	Dorzolamide, acetazolamide	↓ aqueous production	Topical/oral
Cholinomimetics	Pilocarpine, carbachol	↑ trabecular outflow (miosis)	Topical
ROCK inhibitors	Netarsudil	↑ trabecular outflow	Topical
Osmotic agents	Mannitol, glycerol	↓ vitreous volume (acute crisis)	IV/oral

Osmotic Agents (for Acute Angle-Closure Crisis):

Mannitol (IV) and Glycerol (oral) - create osmotic gradient to draw fluid out of vitreous → reduce IOP rapidly in emergencies
Short-term use only; systemic effects (volume expansion)

Sources: Katzung's Basic and Clinical Pharmacology, 16th Ed.; Lippincott Illustrated Reviews: Pharmacology; Miller's Anesthesia, 10th Ed.; Goodman & Gilman's The Pharmacological Basis of TherapeuticsHere is a complete, detailed set of 8-mark answers for all four sections (c through f), drawn from Katzung, Lippincott, Miller's Anesthesia, and Goodman & Gilman:

QUICK SUMMARY OF KEY EXAM POINTS

Before the full answers, here are the highest-yield facts per section:

c: Pilocarpine = parasympathomimetic + glaucoma drug. Atropine = prototype parasympatholytic. Epinephrine = nonselective sympathomimetic. Clonidine = central sympatholytic (α2 agonist).
d: Succinylcholine = depolarizing, fastest onset (RSI). Rocuronium + sugammadex = best non-depolarizing pair. Dantrolene = malignant hyperthermia.
e: Amides = lidocaine/bupivacaine (two "i"s). Esters = procaine/cocaine (one "i"). Mechanism = Na⁺ channel block from inside. Bupivacaine cardiotoxicity → treat with 20% lipid emulsion.
f: MG = anti-AChR antibodies → pyridostigmine (symptomatic) + prednisolone/azathioprine (disease-modifying) + thymectomy. Glaucoma = prostaglandins (1st line, open-angle), pilocarpine (emergency, both types), timolol (β-blocker), dorzolamide (CAI).

All four sections above are fully written out with classifications, mechanisms, drugs, pharmacological effects, uses, adverse effects, and comparison tables - everything needed for an 8-mark exam answer. Let me know if you want any section expanded further or formatted differently (e.g., as short notes, flowcharts, or mnemonics).

Para sympathetic mymetics in detail for four marks.

Finding Sources

You've run out of free credits. Sign up for a free account to continue using Orris.

This is a shared conversation. Sign in to Orris to start your own chat.